{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:20Z","timestamp":1790217380674,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"publisher","award":["96-2314-B-182A-094"],"award-info":[{"award-number":["96-2314-B-182A-094"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.ophtha.2010.04.018","type":"journal-article","created":{"date-parts":[[2010,7,30]],"date-time":"2010-07-30T04:19:40Z","timestamp":1280463580000},"page":"176-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"title":["Effects and Complications of Bevacizumab Use in Patients with Retinopathy of Prematurity: A Multicenter Study in Taiwan"],"prefix":"10.1016","volume":"118","author":[{"given":"Wei-Chi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ting","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-Ni","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-May","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsi-Kung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2010.04.018_bib1","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","article-title":"Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity","volume":"1","author":"Alon","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.ophtha.2010.04.018_bib2","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/archopht.124.1.24","article-title":"Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP)","volume":"124","author":"Repka","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib4","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/archopht.1996.01100140287005","article-title":"Partial retinal detachment at 3 months after threshold retinopathy of prematurity: long-term structural and functional outcome","volume":"114","author":"Gilbert","year":"1996","journal-title":"Arch Ophthalmol"},{"issue":"suppl","key":"10.1016\/j.ophtha.2010.04.018_bib5","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1097\/IAE.0b013e318158ea0e","article-title":"Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity","volume":"28","author":"Wu","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2010.04.018_bib6","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2010.04.018_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ajo.2009.02.006","article-title":"Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study","volume":"148","author":"Bashshur","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","article-title":"Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2010.04.018_bib9","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2010.04.018_bib10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ajo.2006.04.058","article-title":"Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy","volume":"142","author":"Mason","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","article-title":"Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2010.04.018_bib12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1600-0420.2007.01107.x","article-title":"Intravitreal bevacizumab for vitreous haemorrhage [letter]","volume":"86","author":"Jonas","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-0420.2007.01021.x","article-title":"Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy [letter]","volume":"86","author":"Ruiz-Moreno","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib14","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ajo.2006.06.066","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma","volume":"142","author":"Iliev","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib15","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/bjo.2007.127282","article-title":"Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study","volume":"92","author":"Kriechbaum","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bjo.2008.141085","article-title":"Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial","volume":"93","author":"Prager","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00417-008-0916-2","article-title":"One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion","volume":"247","author":"Jaissle","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib18","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.ophtha.2009.04.026","article-title":"Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity","volume":"116","author":"Sato","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2010.04.018_bib19","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.ophtha.2008.12.023","article-title":"Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity","volume":"116","author":"Sato","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2010.04.018_bib20","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archophthalmol.2008.1","article-title":"Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study [letter]","volume":"126","author":"Kong","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib21","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib22","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","article-title":"Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity","volume":"245","author":"Chung","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"suppl","key":"10.1016\/j.ophtha.2010.04.018_bib23","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":"Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity","volume":"28","author":"Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2010.04.018_bib24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II","volume":"28","author":"Mintz-Hittner","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2010.04.018_bib25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4103\/0301-4738.33057","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity [letter]","volume":"55","author":"Azad","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib26","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1600-0420.2007.01106.x","article-title":"Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity [letter]","volume":"86","author":"dell'Omo","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"38","author":"Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.ophtha.2010.04.018_bib28","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/IAE.0b013e31818a1ee7","article-title":"Off-label use of bevacizumab in retinopathy of prematurity [letter]","volume":"29","author":"Rishi","year":"2009","journal-title":"Retina"},{"issue":"suppl","key":"10.1016\/j.ophtha.2010.04.018_bib29","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":"Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity","volume":"28","author":"Lalwani","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2010.04.018_bib30","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1167\/iovs.08-2584","article-title":"Through the eyes of a child: understanding retinopathy through ROP","volume":"49","author":"Smith","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2010.04.018_bib31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/08820530902800314","article-title":"Retinopathy of prematurity: current concepts in molecular pathogenesis","volume":"24","author":"Heidary","year":"2009","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib32","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0002-9440(10)65004-3","article-title":"Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity","volume":"156","author":"Lashkari","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib33","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1203\/PDR.0b013e31819d9e8c","article-title":"A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants","volume":"65","author":"Lofqvist","year":"2009","journal-title":"Pediatr Res"},{"key":"10.1016\/j.ophtha.2010.04.018_bib34","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity","volume":"246","author":"Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib35","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MOP.0b013e32832925f9","article-title":"Antivascular endothelial growth factor for retinopathy of prematurity","volume":"21","author":"Mintz-Hittner","year":"2009","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.ophtha.2010.04.018_bib36","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/IAE.0b013e3181a3b7ef","article-title":"Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy","volume":"29","author":"Yeh","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2010.04.018_bib37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ophtha.2008.11.005","article-title":"Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment","volume":"116","author":"Oshima","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2010.04.018_bib38","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1073\/pnas.92.3.905","article-title":"Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization","volume":"92","author":"Pierce","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2010.04.018_bib39","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1523\/JNEUROSCI.15-07-04738.1995","article-title":"Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia","volume":"15","author":"Stone","year":"1995","journal-title":"J Neurosci"},{"key":"10.1016\/j.ophtha.2010.04.018_bib40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":"Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES)","volume":"246","author":"Wu","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.04.018_bib41","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0161-6420(01)00695-9","article-title":"Outcomes after laser therapy for threshold retinopathy of prematurity","volume":"108","author":"Foroozan","year":"2001","journal-title":"Ophthalmology"},{"issue":"suppl","key":"10.1016\/j.ophtha.2010.04.018_bib42","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/01.iae.0000244285.79004.e6","article-title":"Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes","volume":"26","author":"Kychenthal","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2010.04.018_bib43","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1395-3907.2003.00171.x","article-title":"Outcome of zone 1 retinopathy of prematurity","volume":"81","author":"O'Keefe","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.ophtha.2010.04.018_bib44","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ophtha.2008.09.035","article-title":"Astigmatism in the Early Treatment for Retinopathy Of Prematurity Study: findings to 3 years of age","volume":"116","author":"Davitt","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2010.04.018_bib45","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ophtha.2007.07.028","article-title":"Progression of myopia and high myopia in the Early Treatment for Retinopathy of Prematurity Study: findings to 3 years of age","volume":"115","author":"Quinn","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2010.04.018_bib46","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0161-6420(96)30487-9","article-title":"Visual fields measured with double-arc perimetry in eyes with threshold retinopathy of prematurity from the Cryotherapy for Retinopathy of Prematurity Trial","volume":"103","author":"Quinn","year":"1996","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164201000446X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164201000446X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:00:57Z","timestamp":1758981657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016164201000446X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S016164201000446X"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2010.04.018","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects and Complications of Bevacizumab Use in Patients with Retinopathy of Prematurity: A Multicenter Study in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2010.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}